These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 28526081)

  • 81. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
    Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
    Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
    [TBL] [Abstract][Full Text] [Related]  

  • 82. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
    Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
    Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico.
    Dutil J; Teer JK; Golubeva V; Yoder S; Tong WL; Arroyo N; Karam R; Echenique M; Matta JL; Monteiro AN
    Sci Rep; 2019 Nov; 9(1):17769. PubMed ID: 31780696
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection.
    Vendrell JA; Vilquin P; Larrieux M; Van Goethem C; Solassol J
    J Mol Diagn; 2018 Nov; 20(6):754-764. PubMed ID: 30055349
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
    Vidal AF; Ferraz RS; El-Husny A; Silva CS; Vinasco-Sandoval T; Magalhães L; Raiol-Moraes M; Barra WF; Pereira CLBL; de Assumpção PP; de Brito LM; Vialle RA; Santos S; Ribeiro-Dos-Santos Â; Ribeiro-Dos-Santos AM
    BMC Cancer; 2021 Apr; 21(1):363. PubMed ID: 33827469
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Repair-Gene Mutations Uncovered in Metastatic Prostate Cancer.
    Cancer Discov; 2016 Sep; 6(9):OF3. PubMed ID: 27460689
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
    Carlo MI; Ravichandran V; Srinavasan P; Bandlamudi C; Kemel Y; Ceyhan-Birsoy O; Mukherjee S; Mandelker D; Chaim J; Knezevic A; Rana S; Fnu Z; Breen K; Arnold AG; Khurram A; Tkachuk K; Cipolla CK; Regazzi A; Hakimi AA; Al-Ahmadie H; Dalbagni G; Cadoo KA; Walsh MF; Teo MY; Funt SA; Coleman JA; Bochner BH; Iyer G; Solit DB; Stadler ZK; Zhang L; Rosenberg JE; Taylor BS; Robson ME; Berger MF; Vijai J; Bajorin DF; Offit K
    J Clin Oncol; 2020 Feb; 38(5):406-414. PubMed ID: 31794323
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
    Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
    BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
    Au CH; Wa A; Ho DN; Chan TL; Ma ES
    Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Mouse models in tumor suppression.
    Ghebranious N; Donehower LA
    Oncogene; 1998 Dec; 17(25):3385-400. PubMed ID: 9917000
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Hereditary prostate cancer - Primetime for genetic testing?
    Heidegger I; Tsaur I; Borgmann H; Surcel C; Kretschmer A; Mathieu R; Visschere P; Valerio M; van den Bergh RCN; Ost P; Tilki D; Gandaglia G; Ploussard G;
    Cancer Treat Rev; 2019 Dec; 81():101927. PubMed ID: 31783313
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
    Singhal D; Hahn CN; Feurstein S; Wee LYA; Moma L; Kutyna MM; Chhetri R; Eshraghi L; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Gao S; Moore S; Das S; Thomas D; Pattnaik S; Brown AL; D'Andrea RJ; Poplawski NK; Thomas D; Scott HS; Godley LA; Hiwase DK
    Leukemia; 2021 Nov; 35(11):3245-3256. PubMed ID: 33850299
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
    Elliott E; Speare V; Coggan J; Espenschied C; LaDuca H; Yussuf AF; Burgess K; Gray P; Cobleigh M; Rao R; Patel J; Kuzel T; Buckingham LE; Usha L
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1287. PubMed ID: 32881420
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].
    Minucci A; Mazzuccato G; Marchetti C; Pietragalla A; Scambia G; Fagotti A; Urbani A
    Mol Biol (Mosk); 2020; 54(4):688-698. PubMed ID: 32840490
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Routine use of gene panel testing in hereditary breast cancer should be performed with caution.
    van Marcke C; De Leener A; Berlière M; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2016 Dec; 108():33-39. PubMed ID: 27931838
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer.
    Plevova P; Walczyskova S; Jeziskova I; Jurckova N; Krepelova A; Puchmajerova A; Pavlikova K; Foretova L; Zapletalova J; Silhanova E
    Neoplasma; 2009; 56(6):500-7. PubMed ID: 19728758
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prevalence of germline variants in inflammatory breast cancer.
    Rana HQ; Sacca R; Drogan C; Gutierrez S; Schlosnagle E; Regan MM; Speare V; LaDuca H; Dolinsky J; Garber JE; Overmoyer BA
    Cancer; 2019 Jul; 125(13):2194-2202. PubMed ID: 30933323
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The genetic basis of breast cancer and its clinical implications.
    Bennett IC; Gattas M; Teh BT
    Aust N Z J Surg; 1999 Feb; 69(2):95-105. PubMed ID: 10030809
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Germline mutations in a DNA repair pathway are associated with familial colorectal cancer.
    Xu P; Sun D; Gao Y; Jiang Y; Zhong M; Zhao G; Chen J; Wang Z; Liu Q; Hong J; Chen H; Chen YX; Fang JY
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.